Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

INSITUMUT

Financiado

Cerrado

Direct detection of cancer causing mutations in tumour specimens

Cancers develop because they acquire changes (mutations) in a specific set of genes that promote their growth. Different mutations are associated with cancer aggressiveness, patient prognosis and/or the response to treatment. Alth... ver más

31/08/2019

UoB

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

THE UNIVERSITY OF BIRMINGHAM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-08-31

ERC-PoC-2016: ERC-Proof of Concept-2016

I+D

Cerrada hace 9 años

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UoB

149.69K€ | Lider

AUTO-JUNTAS

780.50K€ | Participante

Proyectos interesantes

RTC2019-006918-1

Medical Technol...

Data Science

407K€ Cerrado

CPP2021-009037

Medical Technol...

Data Science

474K€ Cerrado

MultiCloneSeq

Medical Technol...

Data Science

150K€ Cerrado

SAF2015-64157-R

Medical Technol...

Data Science

182K€ Cerrado

ONCOTECT

Medical Technol...

Data Science

71K€ Cerrado

FG_WIT

Medical Technol...

Data Science

75K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 20 meses Fecha Inicio: 2017-12-08
Fecha Fin: 2019-08-31

Líder del proyecto

THE UNIVERSITY OF BIRMINGHAM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancers develop because they acquire changes (mutations) in a specific set of genes that promote their growth. Different mutations are associated with cancer aggressiveness, patient prognosis and/or the response to treatment. Although these mutations can usually be detected by extracting DNA from tumour specimens, this provides incomplete information because it is common for mutations not to occur in every cell that makes up the cancer. In a number of research and clinical settings, it is of great use to learn which regions or cells within a cancer carry a particular mutation. To do this, we need to detect mutations in space by examining sections of tissue. There are several potential benefits, including sensitive detection of cancer cells that have been left behind after operation or that will cause relapse after treatment. Here, we shall develop a method to detect mutations in situ in cancer specimens. The INSITUMUT technique uses molecular probes that are specific to mutations in cancer genes and bind to RNA expressed from those genes. We have piloted the method successfully in collaboration with Advanced Cellular Diagnostics Inc., sensitively identifying cancer cells that have acquired specific mutations in the oncogene KRAS and specifically distinguishing them from cells and cancers with normal KRAS. Before making the method available, our workplan in this proposal involves determining probe sensitivity and specificity more accurately, expanding the range of cancer-causing mutations that are detected, developing methods for simultaneous detection of multiple mutations, extending the technique as far as possible to detection of mutations in DNA, and automating the mutation detection process. Subject to technical feasibility and commercial assessments, we shall disseminate the INSITUMUT method to non-profit sectors on a cost recovery basis, and make it generally available as a commercial service in partnership with SME partner Oxford Cancer Biomarkers.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores